Stockwell Lynn, CEO and Executive Chair of Drugs Made In America Acquisition II Corp. ($DMIIU), made two open market purchases of $DMIIU shares worth a total of $0 in the last year, with the latest on September 26, 2025. These rank 4,913th among nearly 5,000 insiders, below the average of $1.5 million across 3.3 transactions. Lynn also sold $DMIIU shares once for $0 total, most recently on September 26, 2025, ranking 11,638th among nearly 12,000 insiders versus an average of $8.6 million over 6.4 transactions.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sept. 26, 2025 | Drugs Made In America Acquisition II Corp. | $DMII | Stockwell Lynn | CEO and Exe. Chair of Board | S | Ordinary shares | 7966667 | $0.00 | 6,708,333.0000 | 0 | 54.29% | 0.00% |
| Sept. 26, 2025 | Drugs Made In America Acquisition II Corp. | $DMII | Stockwell Lynn | CEO and Exe. Chair of Board | P | Ordinary shares | 700000 | $0.00 | 15,075,000.0000 | 0 | 4.87% | 0.00% |
| Sept. 26, 2025 | Drugs Made In America Acquisition II Corp. | $DMII | Stockwell Lynn | CEO and Exe. Chair of Board | J | Ordinary shares | 400000 | $0.00 | 14,675,000.0000 | 0 | 2.65% | 0.00% |
| Sept. 26, 2025 | Drugs Made In America Acquisition II Corp. | $DMII | Stockwell Lynn | CEO and Exe. Chair of Board | P | Rights to receive ordinary shares | 700000 | $0.00 | 700,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 18, 2025 | Drugs Made In America Acquisition Corp. | $DMAA | Stockwell Lynn | CEO and Exe. Chair of Board | P | Rights to receive ordinary shares | 30000 | $0.00 | 430,000.0000 | 8,571,429 | 7.50% | 0.35% |
| Feb. 18, 2025 | Drugs Made In America Acquisition Corp. | $DMAA | Stockwell Lynn | CEO and Exe. Chair of Board | P | Ordinary shares | 30000 | $0.00 | 4,188,780.0000 | 8,571,429 | 0.72% | 0.35% |
| Jan. 29, 2025 | Drugs Made In America Acquisition Corp. | $DMAA | Stockwell Lynn | CEO and Executive COB | S | Ordinary shares | 5698363 | $0.00 | 4,158,780.0000 | 8,571,429 | 57.81% | 66.48% |
| Jan. 29, 2025 | Drugs Made In America Acquisition Corp. | $DMAA | Stockwell Lynn | CEO and Executive COB | P | Ordinary shares | 400000 | $0.00 | 10,257.1430 | 8,571,429 | 0.00% | 4.67% |
| Jan. 29, 2025 | Drugs Made In America Acquisition Corp. | $DMAA | Stockwell Lynn | CEO and Executive COB | J | Ordinary shares | 400000 | $0.00 | 9,857,143.0000 | 8,571,429 | 3.90% | 4.67% |
| Jan. 29, 2025 | Drugs Made In America Acquisition Corp. | $DMAA | Stockwell Lynn | CEO and Executive COB | P | Rights to receive ordinary shares | 400000 | $0.00 | 400,000.0000 | 8,571,429 | 9999.99% | 4.67% |
| June 5, 2024 | Bright Green Corp | $BGXXQ | Stockwell Lynn | Director | S | Common Stock | 1000000 | $0.36 | 68,183,658.0000 | 184,758,818 | 1.45% | 0.54% |
| May 23, 2024 | Bright Green Corp | $BGXXQ | Stockwell Lynn | Director | A | Director Stock Option (right to buy) | 122101 | $0.00 | 122,101.0000 | 184,758,818 | 9999.99% | 0.07% |